Kintara Therapeutics ROA 2024

Kintara Therapeutics Aktienanalyse

What does Kintara Therapeutics do?

Kintara Therapeutics Inc is a US-based biosciences company specializing in the development of cancer drugs and other clinical therapies. It was originally founded as DelMar Pharmaceuticals in 2008 before being renamed Kintara Therapeutics in 2019. The company focuses on developing drugs for the treatment of severe types of cancer such as glioblastoma, a particularly aggressive form of brain tumors. In addition, Kintara Therapeutics also develops clinical therapies for a broader range of indications, including breast cancer and lung cancer. Kintara Therapeutics has developed a proprietary technology platform called VAL-083, which is based on the effect of a chemical compound called dianhydrogalactitol (DAG). VAL-083 is being investigated as a potential treatment for various types of cancer, including those that have become resistant to other therapies. VAL-083 has received orphan drug designation status in the United States and Europe. This means that it is considered a promising new therapy for rare and serious diseases, allowing Kintara Therapeutics to have a faster approval process. In addition to the development of VAL-083, Kintara Therapeutics is also conducting a number of clinical trials on other drug candidates in its pipeline. This includes REM-001, a novel photoimmunotherapy drug for the treatment of cutaneous T-cell lymphomas. REM-001 is based on the use of light and a special type of antibodies to selectively destroy cancer cells. Another important area of business for Kintara Therapeutics is academic collaboration. The company works closely with academic institutions such as the Mayo Clinic, Duke University, and the University of California (San Francisco) to develop and test potential therapies. In addition, Kintara Therapeutics has also partnered with IQVIA, a leading provider of clinical study services, in order to achieve optimal results. In addition to the development and commercialization of cancer drugs, Kintara Therapeutics is also committed to responsible corporate governance. The company is dedicated to having a positive impact on patients, healthcare, and society as a whole through its products and business practices. Overall, Kintara Therapeutics has established a reputation as a reliable partner for the development of cancer therapies and other clinical therapies. The company has a strong portfolio of drug candidates and a broad base for collaborations to unleash its potential in healthcare. Kintara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Kintara Therapeutics's Return on Assets (ROA)

Kintara Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Kintara Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Kintara Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Kintara Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Kintara Therapeutics stock

What is the Return on Assets (ROA) of Kintara Therapeutics this year?

The Return on Assets (ROA) of Kintara Therapeutics is -1.37 undefined this year.

What was the ROA of Kintara Therapeutics compared to the previous year?

The ROA of Kintara Therapeutics has increased by -13% compared to the previous year.

What consequences do high ROA have for investors of Kintara Therapeutics?

A high ROA is advantageous for investors of Kintara Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Kintara Therapeutics?

A low ROA can be unfavorable for investors of Kintara Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Kintara Therapeutics affect the company?

An increase in ROA of Kintara Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Kintara Therapeutics impact the company?

A reduction in the ROA of Kintara Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Kintara Therapeutics?

Some factors that can influence the ROA of Kintara Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Kintara Therapeutics important for investors?

The ROA of Kintara Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Kintara Therapeutics take to improve ROA?

To improve ROA, Kintara Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Kintara Therapeutics pay?

Over the past 12 months, Kintara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kintara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Kintara Therapeutics?

The current dividend yield of Kintara Therapeutics is .

When does Kintara Therapeutics pay dividends?

Kintara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kintara Therapeutics?

Kintara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Kintara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kintara Therapeutics located?

Kintara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kintara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kintara Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Kintara Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Kintara Therapeutics in the year 2023?

In the year 2023, Kintara Therapeutics distributed 0 USD as dividends.

In which currency does Kintara Therapeutics pay out the dividend?

The dividends of Kintara Therapeutics are distributed in USD.